Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.

Kim, Jwa Hoon; Kim, Gi Hwan; Ryu, Yeon-Mi; Kim, Sang-Yeob; Kim, Hyung-Don; Yoon, Shin Kyo; Cho, Yong Mee; Lee, Jae Lyun

Kim, Jwa Hoon; Kim, Gi Hwan; Ryu, Yeon-Mi; Kim, Sang-Yeob; Kim, Hyung-Don; Yoon, Shin Kyo; Cho, Yong Mee; Lee, Jae Lyun.

Afiliação

Kim JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim GH; Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Ryu YM; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim SY; Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim HD; Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Yoon SK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Cho YM; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Lee JL; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Front Oncol ; 12: 969569, 2022.

Article em En | MEDLINE | ID: mdl-36237314